Fungi are major contributors to the opportunistic infections that affect patients with HIV/AIDS.
Systemic infections are mainly with Pneumocystis jirovecii (pneumocystosis), Cryptococcus …

The substantial decline in the Pneumocystis jirovecii pneumonia (PCP) incidence in HIV-
infected patients after the introduction of antiretroviral therapy (ART) in resource-rich settings …

Importance Antiretroviral therapy (ART) is the cornerstone of prevention and management of
HIV infection. Objective To evaluate new data and treatments and incorporate this …

Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has significantly improved
outcomes in the treatment of refractory or relapsed large B-cell lymphoma (LBCL). We …

Background The correct management of immunocompromised patients with pneumonia is
debated. We evaluated the prevalence, risk factors, and characteristics of …

Historically, fungal infections were viewed as a relatively uncommon cause of clinically
relevant disease compared with other bacterial and viral pathogens. 1 This trend shifted in …

ABSTRACT Introduction: Pneumocystis pneumonia (PcP) has classically been described as
a serious complication in patients infected with the human immunodeficiency virus (HIV) …

Infectious diseases, also known as transmissible or communicable diseases, are caused by
pathogens or parasites that spread in communities by direct contact with infected individuals …

Background Pneumocystis jirovecii pneumonia (PJP) is an opportunistic, life-threatening
disease commonly affecting immunocompromised patients. The distribution of predisposing …

There are over 170 known species and subspecies of mycobacteria that have been
identified, and new species continue to be discovered (http://www. bacterio …